Content overview: “Safety Concerns Mount Over Neurocrine Biosciences' Rare Disease Drug Ingrezza”. Patient advocates and medical experts are raising urgent safety concerns about Ingrezza, a rare disease drug from Neurocrine Biosciences used to treat tardive dyskinesia and Huntington's disease chorea. The drug, which generated over $1.4 billion in sales last year, is facing scrutiny over potential side effects including depression, suicidal ideation, and other neuropsychiatric issues. While the FDA has required a boxed warning for depression and suicidal thoughts, critics argue that post-marketing surveillance data suggests the risks may be understated.
Patient advocacy groups, including the Huntington's Disease Society of America, are calling for more transparent reporting and additional studies. Neurocrine maintains the drug's safety profile is well-established, pointing to clinical trials and real-world evidence. However, the growing chorus of concern highlights the challenge of balancing rare disease treatment benefits against potential harms, especially for vulnerable patient populations. For the complete material, the listing points back to the source inside the network.